SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma

類似資料

• P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
  著者:: Chiara Rusconi, 等
  出版事項: (2022-10-01)
• P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
  著者:: Chiara Rusconi, 等
  出版事項: (2023-08-01)
• P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
  著者:: Chiara Rusconi, 等
  出版事項: (2022-10-01)
• Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
  著者:: Paolo Corradini, 等
  出版事項: (2020-06-01)
• Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease
  著者:: Otsuji N, 等
  出版事項: (2024-06-01)